Search results for "blood coagulation"

showing 4 items of 154 documents

Ultrasound-induced blood clot dissolution without a thrombolytic drug is more effective with lower frequencies.

2004

<i>Background and Purpose:</i> Therapeutic ultrasound as stand-alone therapy or in combination with rt-PA has proven to be an effective measure for recanalisation of acute vessel occlusion in different in vitro and in vivo studies. Uncertainty still exists concerning the optimal frequency and intensity with regard to the thrombolytic efficacy of ultrasound. The purpose of this study was a direct comparison of different ultrasound frequencies, when otherwise using identical measurement settings and parameters. <i>Methods:</i> Ultrasound-induced dissolution of fresh human blood clots was studied in a flow system using low-frequency continuous wave ultrasound of 20, 40 …

medicine.medical_specialtymedicine.medical_treatmentVessel occlusionThrombolytic drugInternal medicinemedicineHumansThrombolytic TherapyUltrasonicsStrokeBlood CoagulationUltrasonographyTherapeutic ultrasoundbusiness.industryUltrasoundAnticoagulantsThrombolysisFrequency dependencemedicine.diseaseRecombinant ProteinsSurgeryBloodNeurologyCalibrationCardiologyNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessCerebrovascular diseases (Basel, Switzerland)
researchProduct

F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes.

2022

Background Circulating dysfunctional factor IX (FIX) might modulate distribution of infused FIX in hemophilia B (HB) patients. Recurrent substitutions at FIX activation sites (R191-R226, >300 patients) are associated with variable FIX activity and antigen (FIXag) levels. Objectives To investigate the (1) expression of a complete panel of missense mutations at FIX activation sites and (2) contribution of F9 genotypes on the FIX pharmacokinetics (PK). Methods We checked FIX activity and antigen and activity assays in plasma and after recombinant expression of FIX variants and performed an analysis of infused FIX PK parameters in patients (n = 30), mostly enrolled in the F9 Genotype and PK HB …

medicine.medical_specialtypharmacogenetics.Mutation MissenseSocio-culturaleAlpha (ethology)aemophilia Brecombinant proteinsHemophilia Blaw.inventionFactor IXAntigenlawInternal medicineGenotypemedicineMissense mutationHumansHaemophilia BpharmacokineticBeta (finance)Factor IXpharmacogeneticsChemistryHematologymedicine.diseaseEndocrinologyPhenotypefactor IX activation; hemophilia B; pharmacogenetics; pharmacokinetics; recombinant proteinsRecombinant DNAFemalefactor IX activationBlood Coagulation Testspharmacokineticsrecombinant proteinmedicine.drugJournal of thrombosis and haemostasis : JTH
researchProduct

Advances in surfaces and osseointegration in implantology. Biomimetic surfaces

2015

The present work is a revision of the processes occurring in osseointegration of titanium dental implants according to different types of surfaces -namely, polished surfaces, rough surfaces obtained from subtraction methods, as well as the new hydroxyapatite biomimetic surfaces obtained from thermochemical processes. Hydroxyapatite’s high plasma-projection temperatures have proven to prevent the formation of crystalline apatite on the titanium dental implant, but lead to the formation of amorphous calcium phosphate (i.e., with no crystal structure) instead. This layer produce some osseointegration yet the calcium phosphate layer will eventually dissolve and leave a gap between the bone and …

medicine.medical_treatmentDentistryintegrationReviewcoatingsApatitelaw.inventionlawBiomimetic MaterialsImplants surfacesbioactive titaniumBiomimetics surfacesAmorphous calcium phosphateComposite materialCrystallizationDental implantTitaniumSuperfícies biomimètiquesImplantes dentalesSuperfícies d’implants:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludbone-formation adjacentSuperficies biomiméticasvisual_artUNESCO::CIENCIAS MÉDICASvisual_art.visual_art_mediumacidvivoLayer (electronics)biomimetics surfacesTitaniumMaterials scienceSurface Propertiesproliferationchemistry.chemical_elementOdontología616.3in-vitro:Enginyeria dels materials [Àrees temàtiques de la UPC]OsseointegrationBacterial colonizationfibronectinOsseointegrationmedicineAnimalsHumansGeneral DentistryBlood CoagulationDental ImplantsOral Medicine and PathologyImplants dentalsbusiness.industryDental implantsosseointegrationTitaniimplants surfacesSuperficies de implantesOtorhinolaryngologychemistryOsteointegraciónSurgerybusinessOsteointegració
researchProduct

Interaction of allopurinol with phenprocoumon in man.

1977

Conditions in two patients on long-term phenprocoumon (Marcumar®) treatment are reported who had signs of phenprocoumon overdosage when given simultaneously allopurinol. The determination of phenprocoumon plasma concentrations in one patient showed that phenprocoumon accumulates for several weeks during treatment with allopurinol. Signs of phenprocoumon overdosage thus can appear long time after starting allopurinol treatment.

musculoskeletal diseasesAdultMalecongenital hereditary and neonatal diseases and abnormalitiesAllopurinolMyocardial InfarctionAllopurinolPharmacologyPhenprocoumonDrug DiscoveryMedicineHumansDrug InteractionsBlood CoagulationGenetics (clinical)integumentary systembusiness.industrynutritional and metabolic diseasesGeneral Medicine4-HydroxycoumarinsDrug interactionMiddle AgedPlasma concentrationPhenprocoumonMolecular MedicineBlood Coagulation TestsbusinessMathematicsmedicine.drugKlinische Wochenschrift
researchProduct